Co-pathology may impact outcomes of amyloid-targeting treatments: clinicopathological results from two patients treated with aducanumab

Acta Neuropathol. 2023 Nov;146(5):777-781. doi: 10.1007/s00401-023-02631-8. Epub 2023 Sep 19.
No abstract available

Keywords: Aducanumab; Alzheimer’s disease; Amyloid; Clinicopathological correlation; Lewy body disease.

Publication types

  • Case Reports
  • Research Support, N.I.H., Extramural
  • Letter

MeSH terms

  • Alzheimer Disease* / drug therapy
  • Alzheimer Disease* / pathology
  • Amyloid
  • Amyloid beta-Peptides
  • Amyloidogenic Proteins
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Humans

Substances

  • aducanumab
  • Antibodies, Monoclonal, Humanized
  • Amyloid
  • Amyloidogenic Proteins
  • Amyloid beta-Peptides